Retinoic acid (Tretinoin)
别名: All-trans Retinoic Acid, ATRA, Vitamin A acid,NSC 122758 中文名称：维A酸
此产品请避光密封保存。
Retinoic acid (Tretinoin)是 Retinoic acid receptor (RAR) 和Retinoid X receptor (RXR)的配体，作用于急性早幼粒细胞白血病（APL）细胞，诱导粒细胞分化和凋亡。
Retinoic acid (Tretinoin) Chemical Structure
CAS: 302-79-4
产品质控
批次：
纯度：
99.89%
99.89
Retinoic acid (Tretinoin)相关产品
| 相关靶点 | RAR RXR | 点击展开 |
|---|---|---|
| 相关产品 | TTNPB AM580 Tamibarotene UVI 3003 Fenretinide SR 11237 | 点击展开 |
| 相关化合物库 | 代谢化合物库 抗癌代谢化合物库 谷氨酰胺代谢化合物库 糖代谢化合物库 脂代谢化合物库 | 点击展开 |
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HL60 | Function assay | 2 uM | 48 hrs | Induction of differentiation in human HL60 cells assessed as increase in CD11b positive cells at 2 uM incubated for 48 hrs by 7-AAD staining-based flow cytometric analysis | 31408809 |
| SH-SY5Y | Function assay | 10 uM | 72 hrs | Induction of neurogenesis in human SH-SY5Y cells assessed as stimulation of neurite outgrowth at 10 uM incubated for 72 hrs by phase contrast microscopic analysis | 30996781 |
| SH-SY5Y | Function assay | 10 uM | 24 hrs | Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of MAP-2 mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis | 30996781 |
| SH-SY5Y | Function assay | 10 uM | 24 hrs | Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of N-myc mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis | 30996781 |
| SH-SY5Y | Function assay | 10 uM | 24 hrs | Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of GAP43 mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis | 30996781 |
| NB4 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD14 positive cells at 10 to 30 uM after 6 days by FITC staining based flow cytometry analysis | 30925338 |
| HL60 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human HL60 cells assessed as increase in CD14-FITC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis | 30925338 |
| NB4 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD11c-APC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis | 30925338 |
| HL60 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human HL60 granulocytic assessed as increase in CD11c-APC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis | 30925338 |
| NB4 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD11b-APC-Cy7 positive cells at 10 to 30 uM after 6 days by flow cytometry analysis | 30925338 |
| NB4 | Function assay | 30 uM | 72 hrs | Inhibition of colony formation in human NB4 cells at 30 uM preincubated for 72 hrs followed by compound washout and measured after 7 to 10 days | 30925338 |
| HL60 | Function assay | 30 uM | 72 hrs | Inhibition of colony formation in human HL60 cells at 30 uM preincubated for 72 hrs followed by compound washout and measured after 7 to 10 days | 30925338 |
| NB4 | Antiproliferative assay | 1 to 30 uM | 3 days | Antiproliferative activity against human NB4 cells assessed as reduction in viability at 1 to 30 uM after 3 days by SRB assay | 30925338 |
| HL60 | Antiproliferative assay | 1 to 30 uM | 3 days | Antiproliferative activity against human HL60 cells assessed as reduction in viability at 1 to 30 uM after 3 days by SRB assay | 30925338 |
| HL60 | Function assay | 10 to 30 uM | 6 days | Induction of granulocytic differentiation in human HL60 cells assessed as increase in CD11b-APC-Cy7 positive cells at 10 to 30 uM after 6 days by flow cytometry analysis | 30925338 |
| SH-SY5Y | Function assay | 0.001 to 1 uM | 8 hrs | Transactivation of RARbeta in human SH-SY5Y cells assessed as increase in CYP26A1 mRNA expression at 0.001 to 1 uM measured after 8 hrs by RT-PCR analysis | 29439915 |
| SH-SY5Y | Function assay | 0.001 to 1 uM | 8 hrs | Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARbeta mRNA expression at 0.001 to 1 uM measured after 8 hrs by RT-PCR analysis | 29439915 |
| SH-SY5Y | Function assay | 10 uM | 4 to 12 hrs | Transactivation of RARbeta in human SH-SY5Y cells assessed as increase in CYP26A1 mRNA expression at 10 uM measured after 4 to 12 hrs by RT-PCR analysis | 29439915 |
| SH-SY5Y | Function assay | 10 uM | 4 to 12 hrs | Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARbeta mRNA expression at 10 uM measured after 4 to 12 hrs by RT-PCR analysis | 29439915 |
| TERA2.cl.SP12 | Function assay | 10 uM | 7 days | Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in A2B5 expression at 10 uM measured after 7 days by immunofluorescence method | 29439915 |
| TERA2.cl.SP12 | Function assay | 10 uM | 7 days | Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on A2B5 expression at 10 uM after 7 days by flow cytometric analysis | 29439915 |
| TERA2.cl.SP12 | Function assay | 10 uM | 7 days | Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on TRA160 expression at 10 uM after 7 days by flow cytometric analysis | 29439915 |
| TERA2.cl.SP12 | Function assay | 10 uM | 7 days | Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on SSEA3 expression at 10 uM after 7 days by flow cytometric analysis | 29439915 |
| SK-N-AS | Cell cycle assay | 4 uM | 24 hrs | Cell cycle arrest in human SK-N-AS cells assessed as accumulation at sub-G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometry | 28927789 |
| SK-N-AS | Cell cycle assay | 4 uM | up to 72 hrs | Cell cycle arrest in human SK-N-AS cells at 4 uM up to 72 hrs by propidium iodide staining based flow cytometry | 28927789 |
| SH-SY5Y | Function assay | 10 uM | 10 days | Induction of neuronal differentiation in human SH-SY5Y cells assessed as extensive neurites formation at 10 uM followed by culture medium replacement for every three days for 10 days by inverted-phase microscopic analysis | 28863358 |
| HL60 | Function assay | 0.1 to 10 uM | 5 days | Induction of cell differentiation in human HL60 cells at 0.1 to 10 uM measured after 5 days by NBT/MTT assay | 26832215 |
| HL60 | Function assay | 0.1 to 10 uM | 3 days | Induction of cell differentiation in human HL60 cells at 0.1 to 10 uM measured after 3 days by NBT/MTT assay | 26832215 |
| NB4 | Antiproliferative assay | 1 uM | 96 hrs | Antiproliferative activity against human NB4 cells assessed as decrease in cell viability at 1 uM after 96 hrs by trypan blue exclusion test | 26005022 |
| HEK293 | Function assay | 0.01 to 0.1 uM | 48 hrs | Agonist activity at RARalpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 0.01 to 0.1 uM after 48 hrs by luciferase reporter gene assay | 25838141 |
| HL60 | Function assay | 0.1 uM | 72 hrs | Induction of CYP26A1 expression in human HL60 cells at 0.1 uM after 72 hrs | 25684424 |
| HL60 | Function assay | 1 uM | 4 days | Induction of RAR-mediated differentiation of human HL60 cells at 1 uM after 4 days by NBT assay | 24799257 |
| F9 | Function assay | 0.01 uM | 48 hrs | Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 0.01 uM after 48 hrs by RT-PCR analysis | 24799257 |
| SH-SY5Y | Function assay | 10 uM | 6 days | Induction of cell differentiation in human SH-SY5Y cells assessed as neural-like differentiation at 10 uM after 6 days using beta3-tubulin and NF200 staining by microscopic analysis | 24262378 |
| NB4 | Cell cycle assay | 1 uM | 24 hrs | Cell cycle arrest in human NB4 cells assessed as increase in accumulation at pre-G1 phase at 1 uM after 24 hrs by FACS analysis | 20491440 |
| P19 | Function assay | 2 to 5 uM | 48 hrs | Induction of neurite outgrowth in mouse P19 cells at 2 to 5 uM after 48 hrs by crystal violet staining | 19821610 |
| U87 | Function assay | 2 to 5 uM | 48 hrs | Induction of neurite outgrowth in human U87 cells at 2 to 5 uM after 48 hrs by crystal violet staining | 19821610 |
| Neuro2a | Function assay | 2 to 5 uM | 48 hrs | Induction of neurite outgrowth in mouse Neuro2a cells at 2 to 5 uM after 48 hrs by crystal violet staining | 19821610 |
| SH-SY5Y | Function assay | 2 to 5 uM | 48 hrs | Induction of neurite outgrowth in human SH-SY5Y cells at 2 to 5 uM after 48 hrs by crystal violet staining | 19821610 |
| SK-N-SH | Function assay | 2 to 5 uM | 48 hrs | Induction of neurite outgrowth in human SK-N-SH cells at 2 to 5 uM after 48 hrs by crystal violet staining | 19821610 |
| LNCAP | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human LNCAP cells assessed as maximal effect at 10 uM after 48 hrs by MTT assay | 19375825 |
| TERA2.cl.SP12 | Function assay | 10 uM | Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in TUJ1 expression at 10 uM measured up to 3 weeks by immunofluorescence method | 29439915 | |
| SH-SY5Y | Function assay | 10 uM | Induction of neuronal differentiation in human SH-SY5Y cells assessed as decrease in cell proliferation at 10 uM followed by culture medium replacement for every three days for 10 days by inverted-phase microscopic analysis | 28863358 | |
| COS-7 | Function assay | 24 hrs | Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay, EC50=0.0012μM | 30792038 | |
| COS-7 | Function assay | 24 hrs | Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay, EC50=0.0012μM | 30792038 | |
| COS-7 | Function assay | 24 hrs | Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay, EC50=0.0006μM | 30792038 | |
| COS-7 | Function assay | 1 day | Transactivation of mouse Gal4-fused RARalpha-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay, EC50=0.00151μM | 29288071 | |
| HEK293T | Function assay | 16 to 24 hrs | Transactivation of human Gal4-DBD-fused RARalpha-LBD expressed in HEK293T cells after 16 to 24 hrs by FRET based beta-lactamase reporter gene assay, EC50=0.00101μM | 29288071 | |
| COS-7 | Function assay | 1 day | Transactivation of mouse Gal4-fused RARbeta-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay, EC50=0.00052μM | 29288071 | |
| COS-7 | Function assay | 1 day | Transactivation of mouse Gal4-fused RARgamma-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay, EC50=0.00022μM | 29288071 | |
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=12.64μM | 25701251 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=12.39μM | 25701251 | |
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=11.64μM | 25701251 | |
| LNCAP | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=10.33μM | 25701251 | |
| MDA-MB-453 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=9.51μM | 25701251 | |
| T47D | Cytotoxicity assay | 48 hrs | Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay, GI50=0.82μM | 25701251 | |
| HEK293T | Function assay | 45 mins | Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis, IC50=28.7μM | 23122865 | |
| COLO205 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay, IC50=37μM | 20405849 | |
| MT3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MT3 cells after 48 hrs by MTT assay, IC50=14μM | 20405849 | |
| HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50=4.3μM | 20405849 | |
| LNCAP | Antiproliferative assay | 48 hrs | Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay, IC50=0.5μM | 19375825 | |
| COS7 | Function assay | 16 hrs | Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay, EC50=0.017μM | 19058965 | |
| COS7 | Function assay | 16 hrs | Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay, EC50=0.012μM | 19058965 | |
| COS7 | Function assay | 16 hrs | Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay, EC50=0.0002μM | 19058965 | |
| MDA-MB-231 | Growth inhibition assay | 5 days | Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay, GI50=10.85μM | 18543902 | |
| PC3 | Growth inhibition assay | 5 days | Growth inhibition of human PC3 cells after 5 days by MTT assay, GI50=7.6μM | 18543902 | |
| Raji | Function assay | 48 hrs | Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs, IC50=0.0154μM | 17503850 | |
| F9 | Function assay | 3 days | Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days, IC50=0.0001μM | 17489579 | |
| LNCaP | Growth inhibition assay | 6 days | Growth inhibition of human LNCaP cells after 6 days by MTT assay, IC50=10μM | 15615521 | |
| PC3 | Growth inhibition assay | 6 days | Growth inhibition of human PC3 cells after 6 days by MTT assay, IC50=2μM | 15615521 | |
| MCF7 | Growth inhibition assay | 6 days | Growth inhibition of human MCF7 cells after 6 days by MTT assay, IC50=0.58μM | 15615521 | |
| T47D | Growth inhibition assay | 6 days | Growth inhibition of human T47D cells after 6 days by MTT assay, IC50=0.006μM | 15615521 | |
| ASK | Function assay | 1 hr | Induction of morphological transformation of rat ASK cells into astrocytes after 1 hr by light microscopy, ED50=10μM | 2849641 | |
| AM-38 | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50=40.3084μM | SANGER | ||
| BT-549 | Growth inhibition assay | Inhibition of human BT-549 cell growth in a cell viability assay, IC50=40.4665μM | SANGER | ||
| CAL-72 | Growth inhibition assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=39.8973μM | SANGER | ||
| KYSE-410 | Growth inhibition assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50=39.8734μM | SANGER | ||
| Calu-6 | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=39.87μM | SANGER | ||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50=39.845μM | SANGER | ||
| TE-5 | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50=39.2767μM | SANGER | ||
| P30-OHK | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=39.6005μM | SANGER | ||
| GAMG | Growth inhibition assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50=37.8254μM | SANGER | ||
| LU-134-A | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=36.6391μM | SANGER | ||
| KS-1 | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=37.6794μM | SANGER | ||
| RH-1 | Growth inhibition assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50=36.1915μM | SANGER | ||
| SK-MEL-28 | Growth inhibition assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50=35.3569μM | SANGER | ||
| EGI-1 | Growth inhibition assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50=35.2918μM | SANGER | ||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=34.8315μM | SANGER | ||
| MSTO-211H | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=34.8177μM | SANGER | ||
| KYSE-510 | Growth inhibition assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50=34.5335μM | SANGER | ||
| A204 | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50=34.3531μM | SANGER | ||
| BALL-1 | Growth inhibition assay | Inhibition of human BALL-1 cell growth in a cell viability assay, IC50=34.0459μM | SANGER | ||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50=33.8446μM | SANGER | ||
| NTERA-S-cl-D1 | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=32.8106μM | SANGER | ||
| A2780 | Growth inhibition assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50=32.5555μM | SANGER | ||
| DoTc2-4510 | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50=31.9219μM | SANGER | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=31.6673μM | SANGER | ||
| DOHH-2 | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=30.5389μM | SANGER | ||
| Ramos-2G6-4C10 | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=29.9893μM | SANGER | ||
| A549 | Growth inhibition assay | Inhibition of human A549 cell growth in a cell viability assay, IC50=29.046μM | SANGER | ||
| A673 | Growth inhibition assay | Inhibition of human A673 cell growth in a cell viability assay, IC50=28.2446μM | SANGER | ||
| NCI-H1623 | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50=28.1796μM | SANGER | ||
| CAMA-1 | Growth inhibition assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=28.0179μM | SANGER | ||
| A4-Fuk | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=26.7218μM | SANGER | ||
| SK-MEL-24 | Growth inhibition assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=26.0032μM | SANGER | ||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=23.4999μM | SANGER | ||
| LU-139 | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=23.2003μM | SANGER | ||
| LB1047-RCC | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=23.0132μM | SANGER | ||
| JVM-3 | Growth inhibition assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50=22.9733μM | SANGER | ||
| UM-UC-3 | Growth inhibition assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50=22.677μM | SANGER | ||
| 23132-87 | Growth inhibition assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50=40.541μM | SANGER | ||
| CAKI-1 | Growth inhibition assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50=22.169μM | SANGER | ||
| CHL-1 | Growth inhibition assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50=22.1242μM | SANGER | ||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50=21.8431μM | SANGER | ||
| J-RT3-T3-5 | Growth inhibition assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50=21.8087μM | SANGER | ||
| SW13 | Growth inhibition assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50=21.4558μM | SANGER | ||
| KNS-42 | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50=20.7488μM | SANGER | ||
| SK-N-AS | Growth inhibition assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50=20.4937μM | SANGER | ||
| COLO-829 | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=20.3353μM | SANGER | ||
| OAW-28 | Growth inhibition assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50=20.3321μM | SANGER | ||
| KG-1 | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50=19.8775μM | SANGER | ||
| ME-180 | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50=19.8713μM | SANGER | ||
| HuO9 | Growth inhibition assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50=19.3158μM | SANGER | ||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=18.8495μM | SANGER | ||
| HSC-3 | Growth inhibition assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50=18.7211μM | SANGER | ||
| HC-1 | Growth inhibition assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50=18.4345μM | SANGER | ||
| 697 | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=17.899μM | SANGER | ||
| COLO-684 | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=16.9273μM | SANGER | ||
| NCI-H82 | Growth inhibition assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50=16.9221μM | SANGER | ||
| NCI-H1770 | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50=16.9058μM | SANGER | ||
| P12-ICHIKAWA | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=16.493μM | SANGER | ||
| DEL | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50=15.3728μM | SANGER | ||
| NCI-H1092 | Growth inhibition assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50=15.2894μM | SANGER | ||
| KMOE-2 | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=14.7887μM | SANGER | ||
| HCC1419 | Growth inhibition assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50=15.2519μM | SANGER | ||
| MS-1 | Growth inhibition assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50=14.5539μM | SANGER | ||
| IGROV-1 | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=13.1381μM | SANGER | ||
| NCI-H292 | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=12.2072μM | SANGER | ||
| NOMO-1 | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50=11.9634μM | SANGER | ||
| CHP-212 | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=10.8494μM | SANGER | ||
| KE-37 | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=10.7515μM | SANGER | ||
| HCC2218 | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=10.3872μM | SANGER | ||
| GP5d | Growth inhibition assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50=10.2637μM | SANGER | ||
| NCI-H1648 | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=9.73617μM | SANGER | ||
| MEG-01 | Growth inhibition assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50=9.61318μM | SANGER | ||
| SCC-15 | Growth inhibition assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50=9.34762μM | SANGER | ||
| NKM-1 | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=8.41009μM | SANGER | ||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=7.68291μM | SANGER | ||
| EW-13 | Growth inhibition assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50=7.61078μM | SANGER | ||
| BPH-1 | Growth inhibition assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50=7.43611μM | SANGER | ||
| A3-KAW | Growth inhibition assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50=7.59637μM | SANGER | ||
| NB14 | Growth inhibition assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50=7.1271μM | SANGER | ||
| ALL-PO | Growth inhibition assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=6.8745μM | SANGER | ||
| KYSE-180 | Growth inhibition assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50=6.7014μM | SANGER | ||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=6.6155μM | SANGER | ||
| KY821 | Growth inhibition assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50=5.70426μM | SANGER | ||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=5.32811μM | SANGER | ||
| DB | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50=4.76519μM | SANGER | ||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=4.44737μM | SANGER | ||
| U-266 | Growth inhibition assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50=4.11829μM | SANGER | ||
| ML-2 | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=4.00439μM | SANGER | ||
| COR-L88 | Growth inhibition assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50=3.85872μM | SANGER | ||
| KARPAS-45 | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=2.59581μM | SANGER | ||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=2.52132μM | SANGER | ||
| ECC10 | Growth inhibition assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50=2.38052μM | SANGER | ||
| NCI-H69 | Growth inhibition assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50=2.26561μM | SANGER | ||
| L-363 | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50=2.06964μM | SANGER | ||
| CTB-1 | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=1.60389μM | SANGER | ||
| ACN | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50=1.64999μM | SANGER | ||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=1.59626μM | SANGER | ||
| JVM-2 | Growth inhibition assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50=1.17316μM | SANGER | ||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=1.44987μM | SANGER | ||
| MOLT-13 | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=1.145μM | SANGER | ||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=1.02621μM | SANGER | ||
| LAMA-84 | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=0.99635μM | SANGER | ||
| RPMI-8226 | Growth inhibition assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50=0.99334μM | SANGER | ||
| CTV-1 | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=0.96282μM | SANGER | ||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=0.72929μM | SANGER | ||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=0.8316μM | SANGER | ||
| SK-NEP-1 | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=0.66231μM | SANGER | ||
| KU812 | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=0.53609μM | SANGER | ||
| EW-3 | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50=0.48028μM | SANGER | ||
| HL-60 | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=0.28491μM | SANGER | ||
| D-283MED | Growth inhibition assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50=0.28262μM | SANGER | ||
| NB13 | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50=0.25664μM | SANGER | ||
| HH | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50=0.19554μM | SANGER | ||
| ATN-1 | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=0.0303μM | SANGER | ||
| MC-IXC | Growth inhibition assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=0.15436μM | SANGER | ||
| MV-4-11 | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.02099μM | SANGER | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay, EC50=1.4μM | ChEMBL | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay, EC50=1.1μM | ChEMBL | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay, EC50=0.9μM | ChEMBL | ||
| F9 | Function assay | Cellular activity on the differentiation was quantified by measure of plasminogen activator in mouse embryonal teratocarcinoma F9 cells, AC50=0.2μM | ChEMBL | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay, EC50=0.007μM | ChEMBL | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay, EC50=0.001μM | ChEMBL | ||
| CV-1 | Function assay | Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay, EC50=0.0007μM | ChEMBL | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| LNCAP | Growth inhibition assay | Growth inhibition of human LNCAP cells by MTT assay, GI50=47.86μM | 25634130 | ||
| PC3 | Growth inhibition assay | Growth inhibition of human PC3 cells by MTT assay, GI50=36.3μM | 25634130 | ||
| CWR22Rv1 | Growth inhibition assay | Growth inhibition of human CWR22Rv1 cells by MTT assay, GI50=25.11μM | 25634130 | ||
| SKBR3 | Growth inhibition assay | Growth inhibition of human SKBR3 cells by MTT assay, GI50=22.9μM | 25634130 | ||
| MDA-MB-468 | Growth inhibition assay | Growth inhibition of human MDA-MB-468 cells by MTT assay, GI50=14.12μM | 25634130 | ||
| MDA-MB-231 | Growth inhibition assay | Growth inhibition of human MDA-MB-231 cells by MTT assay, GI50=14.12μM | 25634130 | ||
| BL-21 (BL3) | Function assay | Inverse agonist activity at human RoRc-LBD fusion protein with GST expressed in BL-21 (BL3) cells assessed as SRC1 coactivator peptide recruitment, EC50=18μM | 24502334 | ||
| NIH3T3 | Function assay | Activity at RARgamma expressed in mouse NIH3T3 cells by R-SAT assay, EC50=0.05012μM | 19239230 | ||
| NIH3T3 | Function assay | Activity at RARbeta1 expressed in mouse NIH3T3 cells by R-SAT assay, EC50=0.02512μM | 19239230 | ||
| NIH3T3 | Function assay | Activity at RARalpha expressed in mouse NIH3T3 cells by R-SAT assay, EC50=0.00631μM | 19239230 | ||
| NIH3T3 | Function assay | Agonist activity at RARbeta2 expressed in mouse NIH3T3 cells by R-SAT assay, EC50=0.00631μM | 19239230 | ||
| HaCaT | Function assay | Increase in transcriptional activity of RARalpha receptor epressed in human HaCaT cells co-transfected with DR5-tk-CAT reporter plasmid assessed as beta-galactosidase activity by CAT-ELISA | 18511283 | ||
| MCF7 | Antiproliferative assay | Antiproliferative effect against human MCF7 cells, IC50=0.5845μM | 15615521 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta, EC50=1.211μM | 12482435 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha, EC50=1.015μM | 12482435 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma, EC50=0.961μM | 12482435 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha, EC50=0.436μM | 12482435 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta, EC50=0.078μM | 12482435 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma, EC50=0.019μM | 12482435 | ||
| HL60 | Function assay | In vitro cytotoxicity against HL60 cells, IC50=11μM | 11128648 | ||
| COS | Function assay | Transcriptional activation in COS cells expressing RAR-alpha, Relative EC30=0.0034μM | 10956201 | ||
| COS | Function assay | Transcriptional activation in COS cells expressing RAR-beta, Relative EC30=0.0022μM | 10956201 | ||
| COS | Function assay | Transcriptional activation in COS cells expressing RAR-gamma, Relative EC30=0.00026μM | 10956201 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR alpha receptor, EC30=0.0011μM | 10762039 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR beta receptor, EC30=0.00069μM | 10762039 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR gamma receptor, EC30=0.00018μM | 10762039 | ||
| CV-1 | Function assay | Relative transcriptional activation in CV-1 cells expressing RAR gamma receptor compared to ATRA, Relative EC30=0.001μM | 10762038 | ||
| CV-1 | Function assay | Relative transcriptional activation in CV-1 cells expressing RAR beta receptor compared to ATRA, Relative EC30=0.001μM | 10762038 | ||
| CV-1 | Function assay | Relative transcriptional activation in CV-1 cells expressing RAR alpha receptor compared to ATRA, Relative EC30=0.001μM | 10762038 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR alpha receptor, EC30=0.00099μM | 10762038 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR beta receptor, EC30=0.00093μM | 10762038 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing RAR gamma receptor, EC30=0.00022μM | 10762038 | ||
| HL-60 | Function assay | Induction of HL-60 cells differentiation over 4 days, ED50=0.12μM | 9572893 | ||
| HL-60 | Cytostatic assay | Cytostatic activity against HL-60 cells, IC50=11μM | 10585206 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha, EC50=0.022μM | 9572893 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma, EC50=0.006μM | 9572893 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta, EC50=0.002μM | 9572893 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha, EC50=0.459μM | 8978832 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta, EC50=0.087μM | 8978832 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma, EC50=0.02μM | 8978832 | ||
| embryonic limb bud cells | Function assay | Inhibition of Chondrogenesis in day 11 embryonic limb bud cells, IC50=0.031μM | 8784454 | ||
| HL-60 | Function assay | Induction of transglutaminase (TGase) activity in HL-60 cells, EC50=0.005μM | 8784454 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta, EC50=1.394μM | 8709094 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma, EC50=1.225μM | 8709094 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha, EC50=1.084μM | 8709094 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha, EC50=0.563μM | 8709094 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta, EC50=0.105μM | 8709094 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma, EC50=0.033μM | 8709094 | ||
| F9 | Function assay | In vitro promotion of plasminogen activator secretion from F9 (murine teratocarcinoma) cells, AC50=0.2μM | 8544175 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells, EC50=1.4μM | 8308867 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells, EC50=1.1μM | 8308867 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells, EC50=0.9μM | 8308867 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells, EC50=0.35μM | 8308867 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells, EC50=0.08μM | 8308867 | ||
| CV-1 | Function assay | Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells, EC50=0.01μM | 8308867 | ||
| leukemia cells | Function assay | The concentration required to inhibit the binding of [3H]ATRA to retinoic acid receptor in human promyelocytic leukemia cells, IC50=0.00063μM | 7636879 | ||
| mouse embryo limb bud cells | Function assay | In vitro inhibition of chondrogenesis in mouse embryo limb bud cells, IC50=0.031μM | 7636843 | ||
| HL-60 cdm-1 | Function assay | Transglutaminase activity in HL-60 cdm-1 cells, EC50=0.005μM | 7636843 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha, EC50=0.007μM | 7490725 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta, EC50=0.001μM | 7490725 | ||
| CV-1 | Function assay | Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma, EC50=0.0007μM | 7490725 | ||
| F9 | Function assay | Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay, ED50=0.0015μM | 2738885 | ||
| F9 | Function assay | Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay, ED50=0.0001μM | 2738885 | ||
| T-47D cells | Proliferation assay | Inhibition of ER positive human breast cancer cell T-47D proliferation, IC50=0.2 μM | 12372520 | ||
| human breast cancer cell SK-BR-3 | Proliferation assay | Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation, IC50=0.0017 μM | 12372520 | ||
| SCC-4 | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50=40.9788μM | SANGER | ||
| LU-135 | Growth inhibition assay | Inhibition of human LU-135 cell growth in a cell viability assay, IC50=41.0418μM | SANGER | ||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=41.4859μM | SANGER | ||
| NB7 | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50=41.6004μM | SANGER | ||
| RPMI-7951 | Growth inhibition assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50=41.6006μM | SANGER | ||
| AU565 | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50=41.7522μM | SANGER | ||
| HCE-4 | Growth inhibition assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50=42.548μM | SANGER | ||
| BE-13 | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=42.5818μM | SANGER | ||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=42.8462μM | SANGER | ||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=43.1561μM | SANGER | ||
| PA-1 | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50=43.7456μM | SANGER | ||
| HSC-4 | Growth inhibition assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50=44.5506μM | SANGER | ||
| DMS-79 | Growth inhibition assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50=45.7028μM | SANGER | ||
| EKVX | Growth inhibition assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50=45.9377μM | SANGER | ||
| NOS-1 | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=46.2764μM | SANGER | ||
| U-118-MG | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=46.3314μM | SANGER | ||
| Daoy | Growth inhibition assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50=47.4651μM | SANGER | ||
| SBC-1 | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=47.5218μM | SANGER | ||
| CAL-51 | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=47.6001μM | SANGER | ||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=48.7628μM | SANGER | ||
| BxPC-3 | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=48.8002μM | SANGER | ||
| MOLT-16 | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=49.2304μM | SANGER | ||
| NCI-H1155 | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50=49.9855μM | SANGER | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Retinoic acid (Tretinoin)是 Retinoic acid receptor (RAR) 和Retinoid X receptor (RXR)的配体，作用于急性早幼粒细胞白血病（APL）细胞，诱导粒细胞分化和凋亡。 | ||
|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Tretinoin通过增加过氧化氢酶活性和还原型谷胱甘肽含量，防止培养的人肾小球系膜细胞中H2O2的细胞毒性，其随剂量和时间改变。Tretinoin培育的系膜细胞导致过氧化氢酶mRNA和γ-谷酰基-半胱氨酸合成酶(催化亚基) mRNA水平增加，后者在还原型谷胱甘肽从头合成中是限速步骤。[1] Tretinoin上调人瘢痕疙瘩衍生的成纤维细胞中基质金属蛋白酶-13和基质金属蛋白酶-8. [2] |
|||
|---|---|---|---|---|
| 体内研究(In Vivo) | ||
| 体内研究活性 | Tretinoin处理的老年雄性Fischer 344大鼠肾皮质中蛋白质含量比对照组老年大鼠低30%，这种作用可能依赖于对肿瘤坏死因子-β1(一种matrigenic细胞因子)和骨桥蛋白(一种具有细胞吸附和趋药性的蛋白质)表达的抑制。[1] 在无毛小鼠真皮结缔组织，Tretinoin能够防止主要类固醇引起的生物力学改变，其有助于萎缩。[3] 在豚鼠体内，Tretinoin与imiquimod结合导致组织病理学上的纹身褪色和色素间隙适度。[4] 在45 CD-1小鼠的皮肤切口上，Tretinoin增加成纤维细胞的分化，但是胶原蛋白的产生量减少。[5] |
|
|---|---|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06097546 | Not yet recruiting | Breast Cancer |
Assiut University |
November 1 2023 | -- |
| NCT05832320 | Recruiting | Acute Promyelocytic Leukemia|Induction Therapy|Oral |
Peking University People''s Hospital |
January 1 2023 | Not Applicable |
| NCT05973084 | Recruiting | SARS CoV 2 Infection|SARS CoV 2 Vaccination |
Boston University|National Institute of Allergy and Infectious Diseases (NIAID)|Malaria Alert Center Kamuzu University of Health Sciences|Burnet Institute |
January 17 2023 | -- |
化学信息&溶解度
| 分子量 | 300.4 | 分子式 | C20H28O2 |
| CAS号 | 302-79-4 | SDF | Download Retinoic acid (Tretinoin) SDF |
| Smiles | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C | ||
| 储存条件(自收到货起) | 3年 -20°C(避光) 粉状 | ||
|
体外溶解度 |
DMSO : 50 mg/mL ( (166.44 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 10 mg/mL (33.28 mM) Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Retinoic acid (Tretinoin) | Retinoic acid (Tretinoin) ic50 | Retinoic acid (Tretinoin) price | Retinoic acid (Tretinoin) cost | Retinoic acid (Tretinoin) solubility dmso | Retinoic acid (Tretinoin) purchase | Retinoic acid (Tretinoin) manufacturer | Retinoic acid (Tretinoin) research buy | Retinoic acid (Tretinoin) order | Retinoic acid (Tretinoin) mouse | Retinoic acid (Tretinoin) chemical structure | Retinoic acid (Tretinoin) mw | Retinoic acid (Tretinoin) molecular weight | Retinoic acid (Tretinoin) datasheet | Retinoic acid (Tretinoin) supplier | Retinoic acid (Tretinoin) in vitro | Retinoic acid (Tretinoin) cell line | Retinoic acid (Tretinoin) concentration | Retinoic acid (Tretinoin) nmr
